Scholarlink

Background <p>Ventilator-associated pneumonia (VAP) affects 30–50% of mechanically ventilated patients with acute brain injury (ABI), exceeding general ICU rates (10–20%) due to aspiration risks and immunosuppression, prolonging ICU stays and morbidity. Although short-course antibiotic prophylaxis (AP; e.g., ceftriaxone) targets early VAP, efficacy in ABI remains debated amid mixed evidence, resistance concerns, and non-endorsement by IDSA/ATS guidelines.</p> Methods <p>We searched PubMed, Cochrane Library, and Web of Science (inception to October 2024) for RCTs and non-RCTs on systemic AP (short-course beta-lactams) for VAP prevention in ABI (TBI, SAH, stroke, post-arrest coma) requiring ventilation ≥ 48&#xa0;h. Primary outcomes: early-onset VAP (≤ 96&#xa0;h), late-onset VAP (&gt; 96&#xa0;h), overall VAP, ICU mortality. Secondaries: mechanical ventilation duration, ICU/hospital length of stay (LOS), time to first VAP. Random-effects meta-analysis; heterogeneity via I<sup>2</sup>; risk of bias (RoB 2.0/ROBINS-I).</p> Results <p>Ten studies (5 RCTs [n = 586], 5 non-RCTs [n = 1,087]; total n = 1,673) were included. AP reduced overall VAP (RR = 0.65, 95% CI: 0.48–0.90, P &lt; 0.001; I<sup>2</sup> = 75.9%) and early-onset VAP (RR = 0.41, 95% CI: 0.33–0.52, P &lt; 0.001; I<sup>2</sup> = 0%; events: 88/754 AP vs. 240/832 control). No effect on late-onset VAP (RR = 1.13, 95% CI: 0.72–1.78, P = 0.07; I<sup>2</sup> = 64.8%) or ICU mortality (RR = 0.91, 95% CI: 0.76–1.08, P = 0.27; I<sup>2</sup> = 0%). Secondaries: Reduced ICU LOS (MD = −&#xa0;2.05&#xa0;days, 95% CI: −&#xa0;3.73 to −&#xa0;0.37, P = 0.01; I<sup>2</sup> = 46%) and hospital LOS (MD = −&#xa0;5.02&#xa0;days, 95% CI: −&#xa0;9.20 to −&#xa0;0.85, P = 0.02; I<sup>2</sup> = 70.8%); no difference in ventilation duration (MD = −&#xa0;1.36&#xa0;days, 95% CI: −&#xa0;2.91 to 0.19, P = 0.09) or time to VAP (MD = 1.04&#xa0;days, 95% CI: −&#xa0;0.87 to 2.95, P = 0.29). RCTs showed low-moderate bias; non-RCTs moderate-serious (confounding).</p> Conclusion <p>Short-course AP reduces early/overall VAP and LOS in ABI without impacting late VAP or mortality, supporting targeted use in high-risk cases (e.g., GCS &lt; 8) per stewardship principles. However, heterogeneity, resistance gaps, and guideline caution warrant larger RCTs with non-ABI comparatives to mitigate selection bias and confirm specificity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of antibiotic prophylaxis for ventilator-associated pneumonia in acute brain injury: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2025年12月11日

查看全文
  • Marcelo Costa,
  • Aurelia Incristi,
  • Justin Lindsay,
  • Filipe Virgilio Ribeiro,
  • Kristen Paradine,
  • Tate Barney,
  • Rahul Manne,
  • Gustavo de Oliveira Almeida,
  • Amelia Liu,
  • Raphael Bertani,
  • Wellingson Silva Paiva

摘要

Background

Ventilator-associated pneumonia (VAP) affects 30–50% of mechanically ventilated patients with acute brain injury (ABI), exceeding general ICU rates (10–20%) due to aspiration risks and immunosuppression, prolonging ICU stays and morbidity. Although short-course antibiotic prophylaxis (AP; e.g., ceftriaxone) targets early VAP, efficacy in ABI remains debated amid mixed evidence, resistance concerns, and non-endorsement by IDSA/ATS guidelines.

Methods

We searched PubMed, Cochrane Library, and Web of Science (inception to October 2024) for RCTs and non-RCTs on systemic AP (short-course beta-lactams) for VAP prevention in ABI (TBI, SAH, stroke, post-arrest coma) requiring ventilation ≥ 48 h. Primary outcomes: early-onset VAP (≤ 96 h), late-onset VAP (> 96 h), overall VAP, ICU mortality. Secondaries: mechanical ventilation duration, ICU/hospital length of stay (LOS), time to first VAP. Random-effects meta-analysis; heterogeneity via I2; risk of bias (RoB 2.0/ROBINS-I).

Results

Ten studies (5 RCTs [n = 586], 5 non-RCTs [n = 1,087]; total n = 1,673) were included. AP reduced overall VAP (RR = 0.65, 95% CI: 0.48–0.90, P < 0.001; I2 = 75.9%) and early-onset VAP (RR = 0.41, 95% CI: 0.33–0.52, P < 0.001; I2 = 0%; events: 88/754 AP vs. 240/832 control). No effect on late-onset VAP (RR = 1.13, 95% CI: 0.72–1.78, P = 0.07; I2 = 64.8%) or ICU mortality (RR = 0.91, 95% CI: 0.76–1.08, P = 0.27; I2 = 0%). Secondaries: Reduced ICU LOS (MD = − 2.05 days, 95% CI: − 3.73 to − 0.37, P = 0.01; I2 = 46%) and hospital LOS (MD = − 5.02 days, 95% CI: − 9.20 to − 0.85, P = 0.02; I2 = 70.8%); no difference in ventilation duration (MD = − 1.36 days, 95% CI: − 2.91 to 0.19, P = 0.09) or time to VAP (MD = 1.04 days, 95% CI: − 0.87 to 2.95, P = 0.29). RCTs showed low-moderate bias; non-RCTs moderate-serious (confounding).

Conclusion

Short-course AP reduces early/overall VAP and LOS in ABI without impacting late VAP or mortality, supporting targeted use in high-risk cases (e.g., GCS < 8) per stewardship principles. However, heterogeneity, resistance gaps, and guideline caution warrant larger RCTs with non-ABI comparatives to mitigate selection bias and confirm specificity.